A Phase I Multiple-Dose Study of RO7021610 in Japanese Patients with Ulcerative Colitis
Latest Information Update: 18 Apr 2022
At a glance
- Drugs Efmarodocokin alfa (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chugai Pharmaceutical
Most Recent Events
- 15 Apr 2022 Status changed from recruiting to completed.
- 04 Jan 2022 New trial record